The strategic planning and assessment of in vivo studies have laid the groundwork for future clinical trials in dogs, opening the door to the veterinary market and providing important cues for further human intervention. The business model was revisited and validated, ensuring the technical solution is better prepared for commercialization, and a new pitch deck was developed to attract investors. An exploratory market assessment identified regulatory issues and opportunities in the veterinary sector, particularly among dog owners, with a focus on expanding into Spain and the UK. The business plan was further improved with updated financials, market analysis, and customer validation, aided by collaboration with Catholic University Porto Business School. FETALDISC engaged in mentoring and training activities to enhance skills in business, financials, entrepreneurship, and leadership, with the CEO participating in several key programs. A strong valorisation strategy was developed to attract investors, leveraging the adjusted business model and knowledge from mentoring activities.
Participation in various events provided valuable networking opportunities and insights into investor expectations. Communication efforts included developing a website, promotional videos, and social media content to promote the project and its impact. The Spine Innovation Forum, organized in collaboration with i3S, brought together diverse stakeholders to discuss and innovate in the spinal health field, fostering collaborations and showcasing groundbreaking research.
To ensure further uptake and success, FETALDISC needs to continue in vivo and clinical studies to validate the safety and efficacy of the biomaterial, and to conduct further research to address veterinarians' concerns about biomaterials of fetal origin. Engaging with investors through the new pitch deck is crucial for securing funding for development and commercialization. Exploring partnerships and collaborations will enhance market access, while developing a comprehensive business plan based on the validated model and securing intellectual property rights will support commercialization efforts. Initial expansion should focus on Europe, particularly Spain and the UK, leveraging connections to the American continent for long-term growth.
Engaging with regulatory entities like DGAV and INFARMED to determine the classification of FETALIX and ensuring compliance with regulatory standards is essential for market entry.
Insights from the collaboration with Catholic University Porto Business School already defined the business plan and financial strategies, with support from Women Leadership Programme business coaches.
Continued participation in mentoring and training programs will enhance business growth, stakeholder negotiation, pitching, and market entry skills. Building a strong valorisation strategy, leveraging networking events, and developing communication materials will attract investors and promote the project's impact. Engaging in science communication activities will continue to raise awareness and inspire future generations reducing the gender gap in the entrepreneurial field.
